Baxter International Inc.’s Stock Price Soars to $34.91, Marking a Remarkable 5.28% Increase

Baxter International Inc. (BAX)

34.91 USD +1.75 (+5.28%) Volume: 11.28M

Baxter International Inc.’s stock price stands at 34.91 USD, witnessing a rise of +5.28% this trading session with a trading volume of 11.28M. Despite the recent surge, the stock has experienced a year-to-date decrease of -9.70%, reflecting its volatile performance.

Latest developments on Baxter International Inc.

Health Care stocks are on the rise today following reports of a potential deal involving Baxter International. The company is said to be in talks with Carlyle to sell its kidney care unit for a whopping $4 billion. This news has caused Baxter’s shares to gain momentum, with investors reacting positively to the possibility of this major spinoff. Analysts at Evercore ISI have also adjusted their price target for Baxter International stock, reflecting the potential impact of this deal on the company’s future. Overall, Baxter International Inc. is outperforming its competitors on the stock market today, with shareholders eagerly awaiting further developments on this front.

Baxter International Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have published a bullish report on Baxter International, highlighting the company’s strong performance in the first quarter of 2024. According to the report, Baxter International exceeded its guidance with 2% growth on a reported basis and 3% at constant currency rates. This growth was driven by strong demand and favorable pricing for a wide range of the company’s products. The analysts attribute this success to Baxter International‘s recent strategic transformation, which has improved global visibility, enhanced accountability, and functional verticalization.

The report titled “Baxter International: Driving Revenue with New Innovations and Competitive Conversions! – Major Drivers” provides valuable insights into the company’s performance and future prospects. Investors can access the full report on Baxter International by visiting Baptista Research‘s profile on Smartkarma. The positive sentiment expressed by the analysts underscores the potential for growth and profitability for Baxter International in the coming quarters.

A look at Baxter International Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Baxter International has a promising long-term outlook. With a high score in Dividend and Value, the company is seen as a strong investment option for those looking for steady returns. However, its lower scores in Growth and Resilience indicate potential challenges in expanding and adapting to market changes in the future. The moderate Momentum score suggests that while the company may not be experiencing rapid growth currently, it is still maintaining a decent level of market interest.

Overall, Baxter International Inc. is a reputable company in the medical products and technologies industry, with a focus on various medical conditions such as hemophilia, kidney disease, and infectious diseases. Its strong performance in Dividend and Value on the Smartkarma Smart Scores bodes well for investors seeking stable returns. However, the lower scores in Growth and Resilience highlight areas where the company may need to focus on improving to ensure long-term success in a competitive market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma